Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 18;10(7):1449.
doi: 10.3390/microorganisms10071449.

Achromobacter Species: An Emerging Cause of Community-Onset Bloodstream Infections

Affiliations

Achromobacter Species: An Emerging Cause of Community-Onset Bloodstream Infections

Burcu Isler et al. Microorganisms. .

Abstract

Background: Case reports and small series indicate that Achromobacter species bloodstream infection (BSI) is most commonly a complication of hospitalization among patients with chronic lung disease. The aim of the present study was to determine the incidence, risk factors, and outcomes of Achromobacter sp. BSI in an Australian population.

Methods: Retrospective, laboratory-based surveillance was conducted in Queensland, Australia (population ≈ 5 million) during 2000-2019. Clinical and outcome data were obtained by linkage to state hospital admissions and vital statistics databases. BSI diagnosed within the community or within the first two calendar days of stay in hospital were classified as community-onset. Community-onset BSIs were grouped into community-associated and healthcare-associated.

Results: During more than 86 million person-years of surveillance, 210 incidents of Achromobacter sp. BSI occurred among 195 individuals for an overall age-and sex-standardized annual incidence of 2.6 per million residents. Older individuals and males were at highest risk (2.9 vs. 2.0 per million, IRR for males 1.5; 95% CI, 1.1-1.9; p = 0.008). Most (153; 73%) cases were of community-onset of which 100 (48%) and 53 (25%) were healthcare- and community-associated, respectively. An increasing proportion of community-onset cases were observed during twenty years of surveillance. Underlying medical illnesses were common with median (interquartile range) Charlson Comorbidity Index (CCI) scores of 3 (1-5). CCI scores of 0, 1, 2, and 3+ were observed in 37 (18%), 27 (13%), 40 (19%), and 105 (50%) of cases, respectively. All but one of the cases were admitted to hospital for a median (interquartile range) length of stay of 12 (5-34) days. All-cause case-fatality rates in hospital by day 30 and by day 90 were 30 (14%), 28 (13%), and 42 (20%), respectively. The 90-day case-fatality rate increased with increasing comorbidity and was 3% (1/37), 11% (3/27), 25% (10/40), and 27% (28/105) among those with Charlson Comorbidity Indices of 0, 1, 2, and 3+, respectively (p = 0.004).

Conclusions: Although comorbidity is an important determinant of risk, most Achromobacter sp. BSI are of community-onset and one-fifth of cases occur in patients without significant underlying chronic co-morbidities. This study highlights the value of population-based methodologies to define the epidemiology of an infectious disease.

Keywords: Achromobacter; bloodstream infection; incidence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Age- and sex-standardized incidence of Achromobacter sp. BSI in Queensland.
Figure 2
Figure 2
Proportions of healthcare-associated, community-associated and hospital-onset BSI due to Achromobacter species between 2000 and 2019.
Figure 3
Figure 3
Age and sex of BSI cases. F, female; M, male; T, total.
Figure 4
Figure 4
The incidence of Achromobacter sp. by geographic location.

References

    1. Parkins M.D., Floto R.A. Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis. J. Cyst. Fibros. 2015;14:293–304. doi: 10.1016/j.jcf.2015.03.012. - DOI - PubMed
    1. Menetrey Q., Sorlin P., Jumas-Bilak E., Chiron R., Dupont C., Marchandin H. Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients’ Lung. Genes. 2021;12:610. doi: 10.3390/genes12050610. - DOI - PMC - PubMed
    1. Høiby N., Bjarnsholt T., Moser C., Jensen P., Kolpen M., Qvist T., Aanaes K., Pressler T., Skov M., Ciofu O. Diagnosis of biofilm infections in cystic fibrosis patients. APMIS. 2017;125:339–343. doi: 10.1111/apm.12689. - DOI - PubMed
    1. Isler B., Kidd T.J., Stewart A.G., Harris P., Paterson D.L. Achromobacter Infections and Treatment Options. Antimicrob. Agents Chemother. 2020;64:e01025-20. doi: 10.1128/AAC.01025-20. - DOI - PMC - PubMed
    1. Duggan J.M., Goldstein S.J., Chenoweth C.E., Kauffman C.A., Bradley S.F. Achromobacter xylosoxidans Bacteremia: Report of Four Cases and Review of the Literature. Clin. Infect. Dis. 1996;23:569–576. doi: 10.1093/clinids/23.3.569. - DOI - PubMed

LinkOut - more resources